Home › Companies › ALX ONCOLOGY HOLDINGS INC. › 2023-2024
Compiled from SEC Form N-PX filings and ALX ONCOLOGY HOLDINGS INC.’s Form 8-K, filed June 17, 2024 (Item 5.07 on EDGAR). Page generated October 14, 2026.
Meeting of June 12, 2024: 5 items on ALX ONCOLOGY HOLDINGS INC.’s Form 8-K, filed June 17, 2024: 3 elected · 2 approved.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024
Explore ALX ONCOLOGY HOLDINGS INC. in the interactive database Compare manager voting policies
These tallies are ALX ONCOLOGY HOLDINGS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 17, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Corey Goodman, Ph.D. | 35,775,363 | -- | -- | 6,616,621 | 5,320,757 | 84% | Elected | — |
| Elect Director: Jason Lettmann | 33,828,276 | -- | -- | 8,563,708 | 5,320,757 | 80% | Elected | — |
| Elect Director: Sophia Randolph, Ph.D. | 28,671,086 | -- | -- | 13,720,898 | 5,320,757 | 68% | Elected | — |
| 2. Advisory Vote on the Compensation of the Company's Named Executive Officers | 40,935,354 | 1,422,239 | 34,391 | -- | 5,320,757 | 97% | Approved | — |
| 3. Ratification of the Appointment of Independent Registered Public Accounting Firm | 47,698,670 | 11,338 | 2,733 | -- | -- | 99.9% | Approved | — |
Source: ALX ONCOLOGY HOLDINGS INC., Form 8-K, filed with the SEC on June 17, 2024 — read the filing on EDGAR.
Each item below shows how the 130 asset managers that disclosed a ALX ONCOLOGY HOLDINGS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
84% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Corey Goodman, Ph.D.
ALX ONCOLOGY HOLDINGS INC.’s own tally for this item (“Elect Director: Corey Goodman, Ph.D.”): 35,775,363 for, 6,616,621 withheld, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Three Class I Directors Each director nominee was duly elected to serve until the 2027 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.”
Support: 84% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 42 asset managers below reported 8,343,089 for, 518,231 withheld, 18,033 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,038,419 | 0 | 0 | 11,266 | For |
| Vanguard | 936,245 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 0 | 262,973 | Withhold |
| T. Rowe Price | 121,933 | 0 | 0 | 0 | For |
| Charles Schwab | 113,684 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 66,211 | Withhold |
| Federated Hermes | 57,913 | 0 | 0 | 0 | For |
| Equitable | 480 | 0 | 0 | 43,519 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 43,344 | Withhold |
| John Hancock | 22,469 | 0 | 6,656 | 0 | Mixed |
| Lincoln Financial | 18,200 | 0 | 0 | 9,955 | Mixed |
| Northern Trust | 19,883 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 13,815 | Withhold |
| Bridge Builder Trust | 0 | 0 | 11,377 | 0 | Abstain |
| Pacific Life | 0 | 0 | 0 | 10,736 | Withhold |
| Global X | 9,458 | 0 | 0 | 0 | For |
| AQR | 0 | 0 | 0 | 8,956 | Withhold |
| Voya | 0 | 0 | 0 | 8,755 | Withhold |
| American Century | 0 | 0 | 0 | 7,925 | Withhold |
| ETFis Series Trust I | 0 | 0 | 0 | 6,566 | Withhold |
| Principal Exchange-Traded Funds | 0 | 0 | 0 | 5,546 | Withhold |
| Principal | 90 | 0 | 0 | 2,935 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 2,963 | Withhold |
| Calvert | 0 | 0 | 0 | 2,790 | Withhold |
| State Street | 2,083 | 0 | 0 | 0 | For |
Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.
Combines 3 wordings of this item as funds reported it.
80% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Jason Lettmann
ALX ONCOLOGY HOLDINGS INC.’s own tally for this item (“Elect Director: Jason Lettmann”): 33,828,276 for, 8,563,708 withheld, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Three Class I Directors Each director nominee was duly elected to serve until the 2027 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.”
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 42 asset managers below reported 1,977,955 for, 6,878,929 withheld, 22,469 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 317,526 | 0 | 0 | 6,732,159 | Withhold |
| Vanguard | 936,245 | 0 | 0 | 0 | For |
| BlackRock | 262,973 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 121,933 | Withhold |
| Charles Schwab | 113,684 | 0 | 0 | 0 | For |
| Aberdeen | 66,211 | 0 | 0 | 0 | For |
| Federated Hermes | 57,913 | 0 | 0 | 0 | For |
| Equitable | 43,519 | 0 | 0 | 480 | For |
| QUANTITATIVE MASTER SERIES LLC | 43,344 | 0 | 0 | 0 | For |
| John Hancock | 6,656 | 0 | 22,469 | 0 | Mixed |
| Lincoln Financial | 28,155 | 0 | 0 | 0 | For |
| Northern Trust | 19,883 | 0 | 0 | 0 | For |
| Goldman Sachs | 13,815 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 11,377 | 0 | 0 | 0 | For |
| Pacific Life | 10,736 | 0 | 0 | 0 | For |
| Global X | 9,458 | 0 | 0 | 0 | For |
| AQR | 8,956 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 0 | 8,755 | Withhold |
| American Century | 0 | 0 | 0 | 7,925 | Withhold |
| ETFis Series Trust I | 6,566 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 5,546 | 0 | 0 | 0 | For |
| Principal | 3,025 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 2,963 | 0 | 0 | 0 | For |
| Calvert | 0 | 0 | 0 | 2,790 | Withhold |
| State Street | 2,083 | 0 | 0 | 0 | For |
Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.
Combines 4 wordings of this item as funds reported it.
68% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Sophia Randolph, M.D., Ph.D.
ALX ONCOLOGY HOLDINGS INC.’s own tally for this item (“Elect Director: Sophia Randolph, Ph.D.”): 28,671,086 for, 13,720,898 withheld, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Three Class I Directors Each director nominee was duly elected to serve until the 2027 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.”
Support: 68% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 42 asset managers below reported 1,800,938 for, 7,055,507 withheld, 22,908 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 317,526 | 0 | 0 | 6,732,159 | Withhold |
| Vanguard | 936,245 | 0 | 0 | 0 | For |
| BlackRock | 262,973 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 121,933 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 113,684 | Withhold |
| Aberdeen | 66,211 | 0 | 0 | 0 | For |
| Federated Hermes | 57,913 | 0 | 0 | 0 | For |
| Equitable | 4,729 | 0 | 0 | 39,270 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 43,344 | 0 | 0 | 0 | For |
| John Hancock | 6,656 | 0 | 22,469 | 0 | Mixed |
| Lincoln Financial | 9,955 | 0 | 0 | 18,200 | Mixed |
| Northern Trust | 19,883 | 0 | 0 | 0 | For |
| Goldman Sachs | 13,815 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 11,377 | 0 | 0 | 0 | For |
| Pacific Life | 10,736 | 0 | 0 | 0 | For |
| Global X | 0 | 0 | 0 | 9,458 | Withhold |
| AQR | 8,956 | 0 | 0 | 0 | For |
| Voya | 8,755 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 7,925 | Withhold |
| ETFis Series Trust I | 6,566 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 5,546 | 0 | 0 | 0 | For |
| Principal | 3,025 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 2,963 | 0 | 0 | 0 | For |
| Calvert | 0 | 0 | 0 | 2,790 | Withhold |
| State Street | 0 | 0 | 0 | 2,083 | Withhold |
Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.
Combines 3 wordings of this item as funds reported it.
97% Approved · of votes cast
Description as filed by funds: Advisory vote to approve named executive officer compensation.
ALX ONCOLOGY HOLDINGS INC.’s own tally for this item (“2. Advisory Vote on the Compensation of the Company's Named Executive Officers”): 40,935,354 for, 1,422,239 against — passed, per its Form 8-K filed June 17, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the proxy statement for the Annual Meeting.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,049,685 | 0 | 0 | 0 | For |
| Vanguard | 936,245 | 0 | 0 | 0 | For |
| BlackRock | 262,973 | 0 | 0 | 0 | For |
| T. Rowe Price | 121,933 | 0 | 0 | 0 | For |
| Charles Schwab | 113,684 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 66,211 | 0 | 0 | Against |
| Federated Hermes | 57,913 | 0 | 0 | 0 | For |
| Equitable | 43,999 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 43,344 | 0 | 0 | 0 | For |
| Northern Lights Fund Trust IV | 33,156 | 0 | 0 | 0 | For |
| John Hancock | 29,125 | 0 | 0 | 0 | For |
| Lincoln Financial | 28,155 | 0 | 0 | 0 | For |
| Northern Trust | 19,883 | 0 | 0 | 0 | For |
| Goldman Sachs | 13,815 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 11,377 | 0 | 0 | 0 | For |
| Pacific Life | 10,736 | 0 | 0 | 0 | For |
| Global X | 9,458 | 0 | 0 | 0 | For |
| AQR | 8,956 | 0 | 0 | 0 | For |
| Voya | 8,755 | 0 | 0 | 0 | For |
| American Century | 0 | 7,925 | 0 | 0 | Against |
| ETFis Series Trust I | 6,566 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 5,546 | 0 | 0 | 0 | For |
| Principal | 3,025 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 2,963 | 0 | 0 | 0 | For |
| Calvert | 0 | 2,790 | 0 | 0 | Against |
Fund voting reports, all 43 managers: 8,831,413 for, 79,805 against, 1,291 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| venBio Partners LLC | 9,699,925 | 0 | 0 | 0 | For |
| Fidelity | 6,801,205 | 0 | 0 | 0 | For |
| Redmile Group, LLC | 4,326,509 | 0 | 0 | 0 | For |
| Vivo Capital, LLC | 4,219,429 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 3,428,204 | 0 | 0 | 0 | For |
| Cormorant Asset Management, LP | 2,290,149 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 1,586,100 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 1,279,037 | 0 | 0 | 0 | For |
| Citadel | 705,257 | 0 | 0 | 0 | For |
| BlackRock | 623,952 | 14,960 | 0 | 0 | For |
| State Street | 492,261 | 25 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 345,529 | 0 | 0 | 0 | For |
| T. Rowe Price | 232,709 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 184,409 | 0 | 0 | 0 | For |
| BANK OF HAWAII | 150,000 | 0 | 0 | 0 | For |
| Northern Trust | 127,943 | 35 | 0 | 0 | For |
| Charles Schwab | 113,684 | 0 | 0 | 0 | For |
| Wellington | 105,267 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 101,142 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 92,200 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 66,211 | 0 | 0 | Against |
| Federated Hermes | 60,236 | 1,409 | 0 | 0 | For |
| Renaissance | 46,103 | 0 | 0 | 0 | For |
| Goldman Sachs | 41,633 | 0 | 0 | 0 | For |
| AllianceBernstein | 38,790 | 0 | 0 | 0 | For |
Institutional-manager reports, all 108 managers: 37,382,746 for, 139,867 against. Showing the 25 largest; see all in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2024.
ALX ONCOLOGY HOLDINGS INC.’s own tally for this item (“3. Ratification of the Appointment of Independent Registered Public Accounting Firm”): 47,698,670 for, 11,338 against — passed, per its Form 8-K filed June 17, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3: Ratification of the Appointment of Independent Registered Public Accounting Firm”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 44 asset managers below reported 8,916,774 for, 57 against, 1,291 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,049,685 | 0 | 0 | 0 | For |
| Vanguard | 936,245 | 0 | 0 | 0 | For |
| BlackRock | 262,973 | 0 | 0 | 0 | For |
| T. Rowe Price | 121,933 | 0 | 0 | 0 | For |
| Charles Schwab | 113,684 | 0 | 0 | 0 | For |
| Aberdeen | 66,211 | 0 | 0 | 0 | For |
| Federated Hermes | 57,913 | 0 | 0 | 0 | For |
| Equitable | 43,999 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 43,344 | 0 | 0 | 0 | For |
| Northern Lights Fund Trust IV | 33,156 | 0 | 0 | 0 | For |
| John Hancock | 29,125 | 0 | 0 | 0 | For |
| Lincoln Financial | 28,155 | 0 | 0 | 0 | For |
| Northern Trust | 19,883 | 0 | 0 | 0 | For |
| Goldman Sachs | 13,815 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 11,377 | 0 | 0 | 0 | For |
| Pacific Life | 10,736 | 0 | 0 | 0 | For |
| Global X | 9,458 | 0 | 0 | 0 | For |
| AQR | 8,956 | 0 | 0 | 0 | For |
| Voya | 8,755 | 0 | 0 | 0 | For |
| American Century | 7,925 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 6,566 | 0 | 0 | 0 | For |
| EDBI Pte Ltd | 5,613 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 5,546 | 0 | 0 | 0 | For |
| Principal | 3,025 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 2,963 | 0 | 0 | 0 | For |
Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 52,100,107 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 13.53% |
| 2 | Vanguard | 1.80% |
| 3 | BlackRock | 0.50% |
| 4 | T. Rowe Price | 0.23% |
| 5 | Charles Schwab | 0.22% |
| 6 | Aberdeen | 0.13% |
| 7 | Federated Hermes | 0.11% |
| 8 | Equitable | 0.08% |
| 9 | QUANTITATIVE MASTER SERIES LLC | 0.08% |
| 10 | Northern Lights Fund Trust IV | 0.06% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | venBio Partners LLC | 18.62% |
| 2 | Fidelity | 13.05% |
| 3 | Redmile Group, LLC | 8.30% |
| 4 | Vivo Capital, LLC | 8.10% |
| 5 | Vestal Point Capital, LP | 6.58% |
| 6 | Cormorant Asset Management, LP | 4.40% |
| 7 | ORBIMED ADVISORS LLC | 3.04% |
| 8 | MPM BioImpact LLC | 2.45% |
| 9 | Citadel | 1.35% |
| 10 | BlackRock | 1.23% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Vanguard Group | 2.93% | 13F |
| Lightstone Ventures, L.P. | 2.62% | 13D |
| Citadel Advisors | 2.40% | 13F |
| Geode Capital | 1.16% | 13F |
| State Street | 1.06% | 13F |
| BlackRock | 0.86% | 13F |
| Northern Trust | 0.47% | 13F |
| Renaissance Technologies | 0.45% | 13F |
| T. Rowe Price | 0.45% | 13F |
| Charles Schwab | 0.40% | 13F |
Percentages above are of 52,100,107 shares outstanding, as reported by ALX ONCOLOGY HOLDINGS INC. on its Form 10-Q dated May 2, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ALX ONCOLOGY HOLDINGS INC.’s 10-Q dated May 2, 2024. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.
At ALX ONCOLOGY HOLDINGS INC.'s shareholder meeting held June 12, 2024, in the 2023-2024 proxy season, 130 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 841 separate fund positions. On the most widely held item on that ballot — Advisory vote to approve named executive officer compensation. — ALX ONCOLOGY HOLDINGS INC.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ALX ONCOLOGY HOLDINGS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 17, 2024.
ALX ONCOLOGY HOLDINGS INC. proxy season coverage: 2023-2024 (this page).
Download data (CSV): ballot items · votes by manager · column guide.